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NDDs are caused by the disruption
of essential neurodevelopmental pro-
cesses. Many genes and mutations are
associated with NDDs, pointing to a het-
erogeneous origin of these disorders.
Genotype–phenotype correlations are
difficult to establish due to the existence
of multiple genetic as well as environ-
mental factors that influence the pheno-
typical outcome. The two-hit model and
the existence of multiple molecular diag-Neurodevelopmental disorders (NDDs) are a class of disorders affecting brain
development and function and are characterized by wide genetic and clinical
variability. In this review, we discuss the multiple factors that influence the
clinical presentation of NDDs, with particular attention to gene vulnerability,
mutational load, and the two-hit model. Despite the complex architecture of
mutational events associated with NDDs, the various proteins involved appear
to converge on common pathways, such as synaptic plasticity/function,
chromatin remodelers and the mammalian target of rapamycin (mTOR) pathway.
A thorough understanding of the mechanisms behind these pathways will
hopefully lead to the identification of candidates that could be targeted for
treatment approaches.noses are important factors that should
be taken into account when addressing
NDDs.
Most of the known NDDs genes belong
to few common frequently affected mo-
lecular pathways. Functional and molec-
ular studies elucidating how different
mutations can disturb the converging
pathways can lead to the identification
of potential targets, thereby opening per-
spectives for future treatment.
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Neurodevelopmental disorders (NDDs) are characterized by an inability to reach cognitive,
emotional, and motor developmental milestones. Typically, NDDs are associated with the disrup-
tion of the tightly coordinated events that lead to brain development. NDDs constitute a serious
health problem in our society, affecting N3% of children worldwide [1]. They have a heteroge-
neous etiology and lead to impaired cognition, communication, adaptive behavior, and psycho-
motor skills. NDDs include autism spectrum disorder (ASD), intellectual disability (ID), attention
deficit hyperactivity disorder, and epilepsy [2,3]. Many studies have suggested that shared
molecular pathways could account for the multiple clinical signs that characterize NDDs [4,5].
Accordingly, comorbidity (see Glossary) of two or more of these disorders is frequently
observed. For instance, a combination of ID, ASD, and epilepsy is commonly reported in individ-
ual patients [6,7]. Identification of the shared pathogenic mechanisms of the different NDDs will
help to explain the aforementioned comorbidity and eventually lead to effective treatment.
In terms of genetics, different types of mutation have been associated with NDDs, including
chromosomal rearrangements, copy number variations, small indels, and point mutations.
Thus, the identification of a potential underlyingmutational event, known asmolecular diagnosis,
is a challenging task that needs to overcome the heterogeneity of this complex array of genetic
variations. Some of the technologies currently used for the molecular diagnosis of NDDs are
summarized in Box 1.
These challenges notwithstanding, recognition of NDD-causing genes is crucial for accurate
genetic counseling and patient management, and represents an essential first step toward a
better understanding of the molecular pathways affected by these disorders.
This review focuses on the molecular etiology of NDDs, starting from genetics and moving to the
functional level. First, we discuss how the study of familial cases improved our understanding of
the complex genetics of NDDs. Second, we consider the genetic factors that determine and
influence the phenotype, such as gene vulnerability, mutational load, and multiple molecular608 Trends in Neurosciences, August 2020, Vol. 43, No. 8 https://doi.org/10.1016/j.tins.2020.05.004
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Glossary
BRG1/BRM-associated factor (BAF)
chromatin remodeling complex: a
chromatin modifier family that uses ATP
energy to alter nucleosomal units in
chromatin structures.
CLIP cells: human-specific caudal late
interneuron progenitors characterized in
organoids by a late midgestational origin
and expression of genes associatedwith
the caudal ganglionic eminence
(i.e., COUP-TFII, PROX1, and EGFR).
Comorbidity: presence of one or more
conditions together with a primary
medical condition. In the context of
NDDs, this refers to the occurrence of
two or more NDD phenotypes in
individual patients.
Epistasis: physical and/or functional
interaction between gene products
responsible for the onset of a given
phenotype.
Gene vulnerability: capability of a
given gene to tolerate potentially
disruptive mutations.
Genetic counseling: process aimed at
advising families with one or more
individuals affected by a genetic
condition. It helps to understand the
genetic contributions to the disease and
to calculate the risk of recurrence of the
disease in the offspring.
Molecular diagnosis: identification of
the mutational event responsible for the
onset of a disease phenotype. To be
distinguished from clinical diagnosis,
which represents instead the recognition
of a specific disease affecting a patient




characterized by altered cortical
architecture, abnormal neuronal/glial
morphology, and intractable seizures as
a consequence of deregulation ofmTOR
signaling.
Multifactorial/polygenic disorder:
disorder characterized by a combination
of genetic and nongenetic factors or by
the combination of different mutational
events.
Multipathway loop: in neurons,
changes in synaptic or neuronal
physiology are subserved by alterations
in dendritic and nuclear events,
operating via cellular feedback
mechanisms. Mutations affecting one
pathway may alter the correct
functionality of different pathways, thus
perturbing the homeostasis of the entire
system.
Box 1. Evolution of the Diagnostic Flowchart of NDDs
Early molecular diagnosis of patients with NDD is essential for genetic counseling, patient management, and medical
intervention.
Previously, G banded karyotype and FMR1 trinucleotide repeat analysis were recommended as a first-tier test for patients
with unexplained NDDs. However, the yield in patients was low [111]. The breakthrough of next-generation sequencing
technologies has led to significant advancements in the identification of the genetic causes of NDDs [1,7,112]. To date,
N900 genes responsible for X-linked, autosomal dominant, or autosomal recessive NDDs have been reported
[113,114]. Due to the correlation of genetic disorders with mutations in protein-coding genes, the cheaper and quicker
whole-exome sequencing (WES) is preferred as a diagnostic tool to the more informative whole-genome sequencing
[115,116]. Different studies highlighted the efficiency of exome sequencing as a diagnostic tool, having a diagnostic yield
up to N40% in patients with NDDs, especially when both biological parents are considered [111] Still, mutations could also
occur in noncoding regions, such as regulatory elements, and alter gene expression levels [111]. DNAmicroarrays are also
frequently used to detect gross chromosomal aberrations otherwise not detectable with conventional WES [117,118]. The
expected diagnostic yield of chromosomal microarray testing is estimated ~10–20% in patients with distinct NDDs [111].
Epigenetic alterations, also escaping WES detection, are frequently observed in the presence of NDDs. Therefore,
various additional methods can be used to detect epigenetic changes, such as PCR, tandem mass spectrometry,
and southern blot.
Trends in Neurosciencesdiagnoses. We also highlight the relevance of the two-hit model in the context of understanding
the genetics of NDDs. Finally, we debate whether the identification of frequently affected cellular
pathways allows circumventing the issue of the wide genetic variability of NDDs and whether the
identification of such pathways could open perspectives for future treatments.
Genetics of NDDs
The identification of the potential genetic causes of NDDs is vital for understanding the molecular
mechanisms responsible for the onset of these disorders and for the delineation of a genotype–
phenotype correlation that could help to monitor the progress of the disorder and to foresee
future complications. Despite the numerous NDD-causative genes identified, many individuals
with NDDs still do not receive a molecular diagnosis. Additionally, phenotype–genotype correla-
tion studies have brought to light that the number and severity of clinical signs can vary substan-
tially among patients with overlapping genetic etiology [8,9]. Thus, missing heritability and
phenotypical variability point to a multifactorial and/or polygenic nature of NDDs.
Familial NDDs represent a useful paradigm for dissecting the contribution of genetic and
nongenetic factors to the pathogenesis of these disorders in the presence of a shared genetic
background. For this reason, numerous studies have been conducted on monozygotic twins
with discordant phenotypes [10–12] or on pedigrees where incomplete penetrance and pheno-
typical variability are observed in the multiple affected offspring [13]. This line of research has
tremendous potential not only for the mere identification of the molecular causes of the disease,
but also for the recognition of risk factors and protective factors. Furthermore, it has the potential
for establishing more accurate genotype–phenotype correlations. Thanks to the study of
inherited NDDs, it has emerged that the phenotypical outcome essentially revolves around two
main principles: gene vulnerability and mutational load (Figure 1A).
Gene vulnerability can be defined as the capability of a given gene to tolerate disruptive variants:
the lower the tolerance towards mutations, the higher the level of vulnerability. Some genes
associated with NDDs are haploinsufficient genes characterized by a striking dosage sensitivity.
These particular genes fall within the category of highly vulnerable genes, and mutations affecting
these genes are associated with significant disease risk. Examples of highly vulnerable genes
include DEPDC5, CACNA1A, and SCN8A, which are discussed later in this section. Disruption
of one of these genes has a high probability of inducing the onset of a disease phenotype alsoTrends in Neurosciences, August 2020, Vol. 43, No. 8 609
Mutational load: genetic burden given




rapamycin (mTOR) pathway: a highly
conserved signaling pathway
ubiquitously expressed in eukaryotic
cells. This pathway controls cell survival,
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Trends in Neurosciencesin the absence of other causative events, thus resulting in monogenic forms of NDDs [14]. For this
reason, mutations affecting these genes are normally subject to a strong negative selective
pressure. Hence, population studies have recognized a reduced number of disruptive variants
in vulnerable genes compared with other genomic loci [14]. In other words, mutations in highly
vulnerable genes can be categorized as rare variants associated with significant disease risk
and high penetrance.
The other end of the vulnerability spectrum comprises those genes that are less sensitive to
disruptive mutations. Variants in these genes are not under negative selective pressure and are
frequently transmitted in families for generations [2,14]. Since single disruptive events affecting
nonvulnerable genes are not disease causing per se, they fall within the category of common
variants with low disease risk. Nonetheless, recent studies have demonstrated that a significant
portion of NDDs with polygenic nature can be attributed to common genetic variants [2,15].
In fact, the additive effects of these mutational events could result in a disease phenotype
[2,15,16]. In these cases, however, the phenotypical outcome depends not only on the sum of
the effects of the single mutations, but also the physical and/or functional interactions between
the affected genes (i.e., epistasis) [17,18]. Epistatic interactions and dosage sensitivity strongly
correlate with the concept of mutational load, which argues that the penetrance and complexity of
a disease phenotype are influenced by the number of disruptive events. For example, loss-of-
function monoallelic mutations in the sodium channels CACNA1A and SCN8A are commonly
associated with a variety of clinical features including movement disorder, ID, ASD, and benign
familial infantile seizures (Figure 1B) [19,20]. In accordance with the aforementioned criteria of
dosage sensitivity and mutational load, inherited germline biallelic mutations of CACNA1A and
SCN8A are associated with more severe phenotypes compared with monoallelic changes
(Figure 1C) [19,20]. The recently reported CACNA1A and SCN8A compound heterozygous pro-
bands are characterized by the presence of epileptic encephalopathy, while the heterozygous
parents and siblings only exhibit mild cognitive impairment without seizure [19,20].
In other cases, a higher mutational load might be determined by a combination of germline and
somatic events, a mechanism known as the two-hit model. In the classic two-hit hypothesis,
a constitutive inherited mutation generates a vulnerable genetic background. A subsequent
somatic hit occurring later during development will then be responsible for the onset of a
disease phenotype or the expansion of already present clinical features (Figure 1E). One exam-
ple of a two-hit model comes from mutations in DEPDC5. Germline heterozygous loss-of-
function mutations affecting DEPDC5 are a major cause of familial refractory focal epilepsies
[21]. A second somatic variant causing biallelic inactivation of DEPDC5 was found to be
responsible for the additional development of focal cortical dysplasia in patients with a severe
phenotype [21,22].
Primary and secondary variants can also occur at genomic loci different from each other, thus
expanding the classic two-hit hypothesis (Figure 1D). Several studies have unveiled the significantFigure 1. Schematic Representation of the Genetic Mechanisms of Neurodevelopment Disorders (NDDs)
(A) Mutational load and degree of vulnerability of the disrupted genes influence the phenotypical outcome. In general, the
higher each of these factors is, the more complex the phenotype will be. (B) Most genetic causes of NDDs (if one excludes
cases of consanguineous marriages) involve mutations arising de novo in the offspring of unaffected parents. (C) Although
less frequently, an autosomal recessive mode inheritance is also observed. In these cases, the proband inherits a
defective allele from each unaffected or mildly affected parent. (D) An increasing number of patients is reported to harbo
dual molecular diagnoses. The different mutations of these patients can arise de novo or be inherited from one or both
parents. (E) In the two-hit hypothesis, an initial inherited variant predisposes the proband to a disease state that reaches
its full phenotypical outcome upon somatic inactivation of the second allele. (F) The cumulative load of inherited common
genetic variants can make the proband more vulnerable to the onset of NDDs.
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Trends in Neurosciencescontribution of multiple molecular diagnoses in the context of NDDs [13,23–25]. In line with the
notion of mutational load, genotype–phenotype correlation analyses have established that indi-
viduals with mutations in multiple genes are more likely to be affected [23] and that the number
of disrupting events positively correlates with the number and severity of the clinical signs
observed [13,24]. For instance, the contribution of different mutational events was recently
dissected in two families characterized by intrafamilial clinical variability. In both families, the addi-
tional clinical features of the probands were explained bymutations at additional loci that were not
present in the less severely affected siblings [13].
The cumulative load of common genetic variants might also represent the first hit that makes the
genetic backgroundmore vulnerable to subsequent pathological events (Figure 1F). In fact, it was
recently reported that the burden resulting from the combination of common variants in families
with a history of NDDs positively correlated with genetic predisposition to lower educational
attainment and ID [2].
Thus, the data currently available in the literature suggest that purely monogenic forms of NDDs
are an exception rather than the rule. Most NDDs cases most likely have a multifactorial and/or
polygenic nature, hence confirming the broad heterogeneity of these disorders at both the clinical
and molecular level. Importantly, the clinical outcomemight also be influenced at various levels by
nongenetic factors, although discussion of environmental factors is beyond the scope of the
current review.
What Has Been Learned from Genetic Profiling in NDDs?
The implementation of next-generation sequencing (NGS) technologies in the diagnostic flow-
chart of NDDs has dramatically increased the percentage of patients who receive a molecular
diagnosis. The identification of the genetic etiology of the disease has important ramifications
for genetic counseling and patient management, since it can lead to a better assessment of the
recurrence risk and gives the possibility to foresee future medical complications. The advances
in the field of genetics have also served as a roadmap for the development of functional genomic
studies aimed at understanding the pathogenic mechanisms associated with the reported muta-
tions. As discussed next, this line of research has elucidated some of the biological pathways
important for the onset of NDDs. The recognition of these networks also offers an opportunity
to overcome the complexities associated with the wide genetic variability, and to develop
targeted therapeutic approaches.
Principal Molecular Pathways Affected in NDDs
Functional studies performed during the past decade have shown that most rare and common
variants associated with NDDs affect genes that have a role in a few conserved pathways
[26–28]. ‘The Psychiatric Cell Map Initiative’ was established a few years ago to understand
the molecular pathophysiology of NDDs and to define the key biological pathways along
temporal and spatial axes [29]. Along these lines, it emerged that both common and rare var-
iants result in the perturbation of the homeostatic equilibrium at different levels (i.e., at a cellular,
circuit, or whole brain level) (reviewed in [30]). In this review, we classify the numerous genetic
variants based on their effects on a discrete number of functional molecular pathways. The
pathways that are examined in detail comprise: (i) protein synthesis; (ii) transcriptional or
epigenetic regulation; and (iii) synaptic signaling (Figure 2). Importantly, many mutations appear
to be ultimately connected in a multipathway loop (reviewed in [30]). In this context, second-
hit mutations in highly vulnerable genes or the accumulation of common variants can affect the
entire loop, hence showing the importance of the aforementioned pathways for the onset of
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Figure 2. Processes Affected in Neurodevelopment Disorders (NDDs) in the Developing and Mature Brain.
NDD risk variants have been found in genes with a role primarily in three critical processes: (i) regulation of protein
synthesis; (ii) transcriptional and epigenetic regulation; and (iii) synaptic signaling, particularly when associated
with synaptic maturation. Homeostasis of these processes can be disturbed during neurogenesis, migration of neurons,
and their differentiation [cf. (A)] in prenatal brain development, or synaptic maturation and proper emergence of
inhibitory/excitatory balance in postnatal development [cf. (B)]. The different NDD-associated variants indicate which
molecular pathways and processes are fundamental to control this exquisite homeostatic equilibrium. Abbreviations:
AP, Action potential; CP, cortical plate; IZ, inner subventricular zone; PSD, postsynaptic density; SVZ, subventricular zone;
VZ, ventricular zone. Figure reproduced courtesy of Jasmin Morandell.
Trends in NeurosciencesImpact of Growth Factors and Amino Acid Signaling on Protein Synthesis
Rare and common NDD-causing variants frequently alter the homeostatic balance of protein
synthesis during neurodevelopment. The phosphatidylinositol 3-kinase (PI3K)-mTOR
represents a key pathway for this balance and mutations affecting this axis have been associated
with several NDDs (also known as mTORopathies) [26,31–35].
mTOR is a highly conserved serine/threonine kinase ubiquitously expressed in eukaryotic cells.
Through two different complexes (mTORC1 and mTORC2), mTOR signaling regulates cellular
metabolism. During embryonic development, mTOR regulates neuronal progenitor proliferation
and differentiation, and neurite outgrowth and elongation, important processes that appear to
be coordinated via mRNA translation and regulation of cell cycle progression and exit [36].
In the adult brain, mTOR participates in additional key processes, such as adult neurogenesis,
learning, memory, circuit refinement, and synaptic plasticity [36,37]. mTOR integrates inputs
from three signaling sources: the growth factor pathway, which comprises the PI3K-AKT-TSC
complex, the energy-sensing arm, which responds to low concentrations of ATP through the
AMPK-TSC complex, and the amino acid-sensing arm, which is the less characterized regulator
of the mTOR pathway and controls the activation of mTORC1 directly through RagGTPases [36].
Multiple variants affecting negative regulators of the growth factor and amino acid-sensing arms
(such as TSC1, TSC2, and PTEN or DEPDC5, NPRL2, and NPRL3, respectively) are known to
cause hyperactivation of mTORC1 and have been reported in individuals with NDDs [38,39].
Mutations in TSC1, TSC2 and signaling proteins that function upstream of the TSC complex,
such as AKT or PTEN, have been observed in individuals with ASD, ID, and epilepsy. By contrast,
loss-of-function mutations in components of the GAP activity toward Rags1 (GATOR1) complex,
such asDEPDC5, have been associatedwith focal epilepsy. Hence, mutations in different mTOR-
regulating signaling arms appear to correlate with different phenotypical outcomes. Importantly,
mouse models with heterozygous mutations in the Tsc or Depdc5 show variable phenotypes
and do not recapitulate all clinical signs observed in humans (Table 1). However, they have
been instrumental in studying the underlying pathogenic mechanisms.Trends in Neurosciences, August 2020, Vol. 43, No. 8 613
Table 1. Haploinsufficient and Conditional Tsc1/2 and Depdc5 Mouse, Rat, and Human Cell-Based Models
Gene Mouse or rat model Human cell-based
model
Mouse phenotype Cellular mechanism affected Refs
Tsc1 Tsc1 +/– KO Impaired memory in MWM, CFC, and
social interaction
Absence of brain pathology [40]
L7-Crea; Tsc1 floxed Social impairments, repetitive behaviors,
and abnormal UV vocalizations (+/–),
impaired memory in MWM (–/–)





Increase of severity of seizures, early
lethality (–/–)
Changes in intrinsic excitability, reduction




Repetitive behavior, increase of
spontaneous seizures (–/–)
Disorganization of thalamic circuit,






Reduction of cognitive flexibility (rescue
by Rptor KO)
Reduction intrinsic excitability, impaired





Abnormal maturation of SST
interneurons, increase PV expression
(+/–, –/–), less synaptic inhibition (–/–)
[45]
Tsc2 Tsc2 +/– KO Impaired memory in MWM, 8 radial arm,
and CFC
Changes in late phase of LTP [41]
Impaired UV vocalization [42]
NEX-Cref; Tsc2
floxed
Early lethality (–/–) Abnormal migration and neuronal
hypertrophy (–/–), increase astrogliosis
(+/–, –/–)
[49]
TSC2 TSC2 +/– Purkinje
cells
Delay cerebellar neuronal maturation,





Somatic hypertrophy, FMRP targets
downregulated, hypersynchronicity
[51]






TSC1 +/–, TSC2 +/–
spheroids
Dysmorphic neurons (only in –/–), change
in neuron:glia differentiation ratio (+/–),






Tsc2 +/–; Fmr1 –/y
Impaired memory in CFC, rescued by
Fmr1 KO
Deficient mGluR-LTD (+/–), rescued by
Fmr1 KO
[43]
Depdc5 Depdc5 +/– rat Lethal (–/–), no seizures (+/–) Dysmorphic neurons (+/–) [60]
Syn1-Creg;Depdc5
floxed
Survival decrease and early onset of
seizures(–/–), any changes (+/–)





30% Depdc5 focal KO developed
spontaneous seizures
Abnormal cortical migration, dysmorphic
neurons
[63]
100% Depdc5 focal KO developed
spontaneous seizures
Noncell-autonomous activation of mTOR [64]
Mouse conditional models studied: aL7-Cre (Purkinje cells), bCamKII-Cre (forebrain mature neurons), cGbx-CreERT (thalamic neurons), dDat-Cre (dopamine neurons),
eSST-Cre (somatostatin interneurons), fNEX-Cre (pyramidal neurons of neocortex), gSyn1-Cre (neuronal cells).
Abbreviations: CFC, contextual fear conditioning; LTD, long-term depression; MWM, Morris Water Maze; PV, parvalbumin interneurons; SST, somatostatin interneurons;
UV, ultrasonic vocalizations.
Trends in NeurosciencesTuberous sclerosis complex (TSC) is an autosomal NDD with variable penetrance caused by mu-
tations in TSC1 (hamartin) or TSC2 (tuberin) and characterized by the presence of benign tumors
(i.e., tubers) in multiple organs, including the brain. Neurological comorbidities include ASD614 Trends in Neurosciences, August 2020, Vol. 43, No. 8
Trends in Neurosciences(observed in 50% of cases), ID (50–60%) and early-onset seizures (80–90%) [38]. Loss-of-
function mutations in TSC1 or TSC2 result in the loss of inhibition of mTORC1. Tsc1 or Tsc2
haploinsufficient mouse models display hippocampal-dependent memory deficits and ASD-like
phenotypes but no tumors or seizures [40–43]. Further studies point to subtle dysfunctions in het-
erozygous conditional mice, associated with the process of maturation of GABAergic cells
[44,45] and ASD features [44,46]. By contrast, homozygous conditional models display a more
severe phenotype, characterized by cognitive impairments, spontaneous seizures, and neuronal
hypertrophy [44–49]. Interestingly, recent evidence using human induced pluripotent stem cell
(iPSC)-derived neurons and spheroids revealed that the level of inhibition of mTOR and neuro-
nal/glial differentiation were strongly affected by a second mutation in the complex [50–53].
Thus, a possible explanation for the lack of a clear genotype–phenotype correlation might rely
on the need for a second-hit mutation. However, a recent study performed on organoids derived
from samples from patients with heterozygous TSC2 revealed that TSC2 heterozygous muta-
tions lead to overproliferation of one specific population of interneuron progenitors (CLIP
cells), which the authors describe as the founder population of TSC tumors. In this model,
second-hit mutations are not causative for the development of the tubers but occur during their
progression. Thus, the role of these human interneurons may explain why heterozygous Tsc1
and Tsc2 mice do not develop a TSC phenotype, and highlight the importance of human cell-
based models for the study of NDDs [54].
Germline and somatic mutations of DEPDC5, NPRL2, and NPRL3 (Table 1) have been identified
as one of the major risk factors for epilepsy [55–58]. These genes encode components of the
GATOR1 complex, a trimeric complex that inhibits mTORC1 lysosomal localization and its inter-
action with Rheb by inactivating Rag GTPases in response to amino acid limitations [59]. Similarly
to Tscmouse models, haploinsufficient and conditional knockout (KO) mouse models of Depdc5
[21,60–64] do not recapitulate the focal epileptic phenotype shown by patients [39], hence
pointing to a second-hit event as the possible cause of focal epilepsy. Accordingly, recent
mouse studies have shown that a second somatic mutation in Depdc5 leads to the development
of focal epilepsy and neuronal migration defects in the cortex [21,63].
Altogether, these data underscore the impact of mutational load and the two-hit model on the de-
lineation of the phenotypical outcome and the importance of taking into account these genetic
factors to fully understand the molecular mechanisms behind NDDs.
Transcriptional and Epigenetic Regulation
Numerous genes associated with NDDs belong to the category of transcriptional regulators or
chromatin remodelers [65]. By regulating the transcript levels of developmental genes in the
brain, this class of proteins controls the maturation of cortical inhibitory and excitatory connec-
tions during development, as well as regulatory networks that drive neuronal specification and
activity-dependent responses. Examples of well-known disease-causing genes classified as
chromatin remodelers or transcriptional regulators include MECP2, SETD5, CHD8, ASH1L,
ARID1B, and KMT2A [66–69]. Given the multiple targets of each of these proteins, dysregulation
of any one of them can show pleiotropic effects. Relatedly, the CHD protein family comprises
multiple isoforms with different roles in the distinct stages of neurodevelopment (reviewed in
[70]), from the early stages of migration to the maturation of synaptic connectivity [71]. Interest-
ingly, various isoforms have been reported in association with distinct neurodevelopmental
phenotypes, namely ID for CHD1 and CHD4, epileptic encephalopathy for CHD2, and
ASD for CHD8 [72–75]. Haploinsufficient mouse models are available for most CHD genes.
For instance, conditional KO of Chd4, encoding one of the core ATPase subunits of the
deacetylation-dependent transcriptional repressor NuRD complex, leads to microcephalyTrends in Neurosciences, August 2020, Vol. 43, No. 8 615
Trends in Neurosciencesand altered connectivity in the cerebellar cortex [71,76]. However, patients with mutations in
this gene are characterized by a marked developmental delay, ID, and macrocephaly [77].
Hence, there are some differences between the phenotype of the mouse model and the
human condition. Likewise, while mutations inCHD8 are tightly associated with ASD in humans
[75], Chd8 heterozygous mutant mice display very mild phenotypes, thus making the function
of CHD8 difficult to interpret [78,79].
Haploinsufficiency of ARID1B, a structural subunit essential for the assembly of the BRG1/
BRM-associated factor (BAF) chromatin remodeling complex [80], is also recognized
as one of the most frequent cause of NDDs and results in a variety of clinical signs, ranging
from sporadic ASD/ID to syndromic disorders [81,82]. Studies in mouse models have uncov-
ered a role of Arid1b and the BAF complex during interneuron migration and differentiation in
early cortical development and in controlling proper neurite outgrowth and maintenance
[83,84]. Interestingly, Arid1b heterozygous mutant mice display a normal density of pyramidal
neurons, but a significant reduction of GABAergic neurons, specifically parvalbumin-positive
neurons (PV) [84].
Over the past few years, loss-of-function mutations affecting the SET-domain containing
5 (SETD5) gene have also been recognized as one of the most frequent causes of ID and
ASD [81]. SETD5 represents an important regulatory link between the transcription machinery
and the activity of a chromatin-modifying transcriptional corepressor complex. For this rea-
son, SETD5 appears to be essential for the regulation of gene expression during early devel-
opment and learning. Accordingly, Setd5 heterozygous mice show dysregulation of the
dynamic expression of synaptic proteins and changes in cell fate determination during early
development [85].
Despite the phenotypical differences between the mouse models and the clinical signs observed
in humans, the haploinsufficient models described in this section highlight the importance of the
correct dosage of chromatin remodelers and transcriptional regulators for the proper execution of
crucial cellular processes during development. The pathogenic mechanism associated with this
class of proteins is linked to global transcriptional disturbances in the cells. The differentially
expressed genes overlap across different cellular models and gene ontology analyses reveal an
enrichment in genes involved in neuronal development, chromatin dynamics, cell cycle regulation,
and RNA [86,87]. Importantly, the dysregulated modules are strongly enriched for known NDD-
risk genes [85–87]. The dysregulation of the NDD genes that occurs in the presence of mutations
in chromatin remodelers and transcriptional regulators also contributes to cellular dysfunction and
further influences the phenotype. Therefore, it is the combination of direct and indirect effects de-
riving from the initial mutation that probably leads to the complex pattern of symptoms observed
in NDDs and that makes the genotype–phenotype correlation difficult to interpret.
Dysregulation of Synaptic Signaling, Transcriptional Changes, and Translational Perturbations
During development, two major groups of synaptic protein contribute to the activity-dependent
formation of neuronal circuits: cell-adhesion molecules (CAMs), which mediate the bidirectional
organization of the pre- and postsynaptic compartments through trans-cellular signaling [88], and
scaffolding and synaptic signaling-associated proteins, located at the postsynaptic density, which
form large molecular networks of receptors and actin-associated proteins [89]. Deleterious variants
in genes encoding these proteins can significantly alter the course of brain development and,
therefore, it is not surprising that they have been repeatedly associatedwith NDDs [89]. For instance,
neurexins (NRXN), neuroligins (NLGN), and SHANKs, proteins with an important role in the pre- and
postsynaptic compartments, have been implicated in NDDs by independent studies in patients and616 Trends in Neurosciences, August 2020, Vol. 43, No. 8
Trends in Neurosciencesmouse models [90–98]. Human neurons carrying loss-of-function mutations in NRXN1 display a
significant synaptic impairment coupled with dysregulated release of the neurotransmitter [91]. By
contrast, a specific missense substitution of NLGN4 or loss-of-function mutations of SHANK2
have been found to induce either an increase of excitatory synapse or hyperconnectivity of excitatory
neurons, respectively [92,93]. Several excellent reviews focus on the role of these and other synaptic
proteins in the context of NDDs. Herein, we describe recent studies indicating the functional and
bidirectional connection of these genes with NDD-risk genes categorized within the other two
pathways reviewed in this article. This connection highlights the modifying role of potentially any
genetic variant affecting other NDD-linked signaling cascade genes on the clinical outcome.
For example, a recent transcriptomic analysis of SHANK2mutant human neurons identified a signif-
icant number of Fragile-X mental retardation protein (FMRP) targets and chromatin/transcriptional
regulators among the differentially expressed genes [93]. In addition, patient studies revealed that
mutations in SHANK2 can coexist with variants in other NDD genes and suggested that these alter-
ations act as phenotypic modifiers [94]. In particular, one patient was found to carry a deletion of
CYFIP1, a cytoplasmic interactor of FMRP that modulates cap-dependent translation of mTOR
[99] as well as the inhibitory:excitatory ratio [100,101]. Therefore, various defects can result from
the simultaneous dysregulation of multiple pathways. Similarly, data obtained in a human model
point to dysregulation of the PI3K pathway in neurons with reduced SHANK3 expression [95].
Additionally, Shank3 haploinsufficient mice show an abnormal level of histone acetylation, which
can be rescued by acute treatment with romidepsin, a class I histone deacetylase inhibitor, thus
linking epigenetic modifications to synaptic scaffolding proteins. Importantly, the inhibition of histone
deacetylase leads to robust and long-lasting rescue of social deficits without affecting locomotor and
anxiety behaviors in youngmice. However, this rescue is limited by the lack of chronic effects in adult
mice, suggesting a time developmental window for the interconnection of synaptic and epigenetics
pathways [96]. SynGAP, the synaptic Ras/RapGTPase-activating protein, is another critical compo-
nent of the postsynaptic density associated with scaffolding proteins involved in the regulation of
AMPA receptors [102]. Patients with SYNGAP1 loss-of function mutations exhibit ID and ASD.
Interestingly, SynGAP heterozygous mice show an increase of protein synthesis due to dysregula-
tion of the mGluR-Erk1/2 signaling pathway, which mimics the molecular pathophysiology associ-
ated with the loss of FMRP in Fmr1 KO mice. Pharmacological manipulation of the mGluR-Erk1/2
signaling pathway rescues behavioral phenotypes in both models [103].
Although CAMs proteins are central regulators of synapse development and specification, human
loss-of-function mutations in NDD-linked cell adhesion molecules (NRXN and NLGN) are not as-
sociated with changes in transcriptional or translational regulators [91,92,97]. This discrepancy
may be explained by gene redundancy. For instance, NRXN1, 2, and 3 have been shown to
have overlapping functions. Thus, mutations in one gene might not be enough to lead to certain
phenotypic features. Similarly, alternative CAMsmay overcome specific deficits in individuals with
mutations in one of these genes. Since the signaling pathways activated by many of these CAMs
are still unknown, a detailed molecular analysis might help to understand convergence between
CAMs. In contrast, it is important to mention that mutations in genes regulating mRNA translation
(e.g., 4eibp2 KO) have been associated with a specific dysregulation of neuroligins, suggesting a
specific link between mTOR and neuroligins [104].
In summary, while significant research attention has focused on the role of synaptic proteins in
NDDs, more recent studies have started to decipher the link between synaptic signaling and reg-
ulation of gene expression and protein synthesis. Future studies are warranted to understand
how transcriptional, translational and synaptic signaling may converge at different developmental
stages and how variants along these processes may functionally interact in NDDs.Trends in Neurosciences, August 2020, Vol. 43, No. 8 617
Outstanding Questions
Rare and common NDD-causing vari-
ants frequently alter the homeostatic
balance of protein synthesis during
neurodevelopment. Compensatory
mechanisms can protect cells to
some degree from the otherwise dele-
terious effects of some mutations. For
example, changes in network activity
can be compensated by neurons by
controlling the strength of their synap-
ses. Analogously, up- or downregula-
tion of certain ion channels represents
a neuronal strategy to alter intrinsic ac-
tivity and adjust neuronal firing. Can we
utilize these compensatory mecha-
nisms to develop future treatments? If
so, are additional consequential mech-
anisms being activated?
Technology is constantly improving,
allowing a better understanding of the
molecular etiology of NDDs. To what
degree will it be possible to translate
the knowledge obtained about NDDs
into clinical applications in the future?
Brain development is a critical and
tightly regulated process, involving
multiple neurobiological pathways,
which establishes the basic functions
of the brain. Are there common
pathways affected in different NDDs
during prenatal or early postnatal
stages? If so, could these common
pathways serve as an early prognosis
signature of the disease?
NGS can help understand the genetic
architecture of NDDs and provides a
substantial amount of information.
However, the application and analysis
of NGS data remain challenging.
Which would be the most effective
methods to cope with this massive
amount of data in terms of analysis
and database management?
Gene therapy approaches are advancing
rapidly, and have already been applied
clinically in a few cases of monogenic
disorders. Does gene therapy represent
a realistic possibility for the treatment
of certain NDDs? How much of an
obstacle, in terms of gene therapy, is
the complex genetics existing in many
of these disorders?
Trends in NeurosciencesConcluding Remarks and Future Perspectives
The study of inherited forms of NDDs has helped to raise awareness of the contribution of multiple
genetic factors to the pathogenesis of these disorders. Despite the broad genetic heterogeneity
of NDDs, the functional consequences of the different mutations appear to converge towards the
disruption of highly interconnected core molecular pathways. These signaling cascades are im-
portant during different critical periods of neurodevelopment as well as in the adult brain [105].
In this review, we focused on changes in nuclear or cytoplasmic functions (i.e., transcription
and translation) that can result, among other issues, in alterations of synaptic homeostasis.
In this context, the severity of the phenotypical outcome may reflect the level of perturbation of
these homeostatic mechanisms [30,106].
Despite these important advancements in the theoretical understanding of NDDs, the road to suc-
cessful treatment is still long (seeOutstandingQuestions). Importantly, the functional convergence of
the genetic causes raises the possibility that drugs targeting these core networks could be used to
reverse some clinical features associated with NDDs. The establishment of reliable models to fully
dissect themolecularmechanisms of NDDs, identify potential targets, and finally test new treatments
represents a crucial step toward this possibility. Animal models aid to disentangle the complex ge-
netic architecture of NDDs and the effects of variousmutations at amolecular and phenotypical level.
For example, ASD is characterized by discrete behaviors, such as impairment in social interaction,
restlessness, and stereotyped behaviors. These complex behaviors can be modeled in mouse
models, thus allowing behavioral analyses in the presence of disease-causing mutations. Accord-
ingly, a detailed description of behavioral phenotypes is currently available for numerous
haploinsufficient mouse models [89]. However, most functional studies in mouse models normally
focus on isolated variants. Still, the phenotypical outcome is strongly influenced by mutational
load, and can often be interpreted in the context of the two-hit model. In other words, the complex
genetic architecture of NDDs, characterized by the presence of multiple variants, underscores the
need to understand the epistatic effects of co-mutations. Additionally, it is also important to under-
score the fundamental differences between animals and humans, especially during development.
Some of these caveats can be addressed using models derived from human iPSCs obtained
from patients with NDD. These models offer a useful complement to the analysis of postmortem
human tissue, by allowing the design of in vitro neural circuits that recapitulate the genetic back-
ground of individuals with NDDs. Hence, they have the potential to lead to personalized treatments
by predicting (at least in vitro) how drugs act on patient-specific molecular pathways, allowing re-
searchers to determine the optimal readout for treatment [107–110]. One major disadvantage of
models derived from human iPSCs is that systemic effects are largely neglected. Therefore, the
combination of human cell-based models and animal models is crucial, especially for a better com-
prehension of the mechanisms leading to the onset of a disease-phenotype. In addition, CRISPR/
Cas9 gene editing offers the possibility to generate multiple gene KOs in the mouse brain and
study their modifying effect when acting simultaneously [21]. Furthermore, the rapid development
of new bioengineering methods represents a promising tool to imitate neural circuit formation and
brain development in 3D. Lastly, single-cell ‘omics approaches, computational models, and
bioinformatics network analysis could complement the aforementioned strategies and support our
understanding of gene expression changes during neuronal development of the human brain. Alto-
gether, these approacheswill allow amore exhaustive comprehension of themolecularmechanisms
underlying NDDs. This knowledge could lead to the development of targeted drugs and to a shift
from the current paradigm of symptomatic treatment toward more resolutive curative treatments.
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